Combining orally available selective estrogen receptor degraders with pan-HER tyrosine kinase inhibitor neratinib in pre-clinical models of HER2+/ER+ breast cancer

Amira Mahdi

doi:Combining orally available selective estrogen receptor degraders with pan-HER tyrosine kinase inhibitor neratinib in pre-clinical models of HER2+/ER+ breast cancer

Combining orally available selective estrogen receptor degraders with pan-HER tyrosine kinase inhibitor neratinib in pre-clinical models of HER2+/ER+ breast cancer

Amira Mahdi

School of Medicine

Research output: Contribution to journal › Article › peer-review

Original language	English (Ireland)
Journal	npj Breast Cancer
DOIs	https://doi.org/Combining orally available selective estrogen receptor degraders with pan-HER tyrosine kinase inhibitor neratinib in pre-clinical models of HER2+/ER+ breast cancer
Publication status	Accepted/In press - 2026

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

Combining orally available selective estrogen receptor degraders with pan-HER tyrosine kinase inhibitor neratinib in pre-clinical models of HER2+/ER+ breast cancer

Cite this

Mahdi, A. (Accepted/In press). Combining orally available selective estrogen receptor degraders with pan-HER tyrosine kinase inhibitor neratinib in pre-clinical models of HER2+/ER+ breast cancer. npj Breast Cancer. https://doi.org/Combining orally available selective estrogen receptor degraders with pan-HER tyrosine kinase inhibitor neratinib in pre-clinical models of HER2+/ER+ breast cancer

@article{f5ac5dc6d3c847a1852fa385e4f1464e,

title = "Combining orally available selective estrogen receptor degraders with pan-HER tyrosine kinase inhibitor neratinib in pre-clinical models of HER2+/ER+ breast cancer",

author = "Amira Mahdi",

year = "2026",

doi = "Combining orally available selective estrogen receptor degraders with pan-HER tyrosine kinase inhibitor neratinib in pre-clinical models of HER2+/ER+ breast cancer",

language = "English (Ireland)",

journal = "npj Breast Cancer",

issn = "2374-4677",

publisher = "NATURE PORTFOLIO",

}

Mahdi, A 2026, 'Combining orally available selective estrogen receptor degraders with pan-HER tyrosine kinase inhibitor neratinib in pre-clinical models of HER2+/ER+ breast cancer', npj Breast Cancer. https://doi.org/Combining orally available selective estrogen receptor degraders with pan-HER tyrosine kinase inhibitor neratinib in pre-clinical models of HER2+/ER+ breast cancer

TY - JOUR

T1 - Combining orally available selective estrogen receptor degraders with pan-HER tyrosine kinase inhibitor neratinib in pre-clinical models of HER2+/ER+ breast cancer

AU - Mahdi, Amira

PY - 2026

Y1 - 2026

U2 - Combining orally available selective estrogen receptor degraders with pan-HER tyrosine kinase inhibitor neratinib in pre-clinical models of HER2+/ER+ breast cancer

DO - Combining orally available selective estrogen receptor degraders with pan-HER tyrosine kinase inhibitor neratinib in pre-clinical models of HER2+/ER+ breast cancer

M3 - Article

SN - 2374-4677

JO - npj Breast Cancer

JF - npj Breast Cancer

ER -